Survival of sublethally irradiated BALB/c hosts given BCL₁tumor cells is markedly improved after wild-type allogeneic BMT.

(A) Survival of control BALB/c mice given irradiation (450 cGy) alone (None) or irradiation and a single intravenous injection of C57BL/6 bone marrow (BM) cells, PBMC, or PBMC and marrow cells. (B) Hosts given an intravenous injection of 0.1 × 10⁶ BCL₁tumor cells (BCL₁ only) or a single dose of 450 cGy sublethal total body irradiation (TBI) and an injection of tumor cells, 13 days earlier (None). Survival of BALB/c hosts given BCL₁tumor cells, sublethal TBI, and bone marrow or PBMC, or PBMC plus marrow cells (BM) cells from C57BL/B6 donors 1 day after TBI is shown in panel B also. (C) Survival of hosts given sublethal TBI, BCL₁ cells, and graded numbers of marrow cells from C57BL/6(B6) donors. (D) Survival of BALB/c hosts given BCL₁tumor cells, sublethal TBI, and a BMT from wild-type (WT), CD4^−/−, CD8^−/−, or TCRα^−/−C57BL/6 donors. There were 5 or 10 hosts in each group.